CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Eugia Pharma Specialities Limited, 2026-08-13
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: On August 13, 2026, the FDA's Center for Drug Evaluation and Research issued a warning letter to Eugia Pharma Specialities Limited (FEI 3011960448, Hyderabad, India) citing significant Current Good Manufacturing Practice violations observed during a February 16-27, 2026 inspection of its sterile injectable drug manufacturing facility. The FDA documented inadequate aseptic processing design—including insufficient restricted access barrier system (RABS) elements, improper ISO 5 area separation, excessive uncontrolled operator interventions, and inadequate environmental monitoring—rendering finished drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The agency found the company's March 20, 2026 response inadequate due to missing retrospective product impact assessment and unresolved RABS design flaws.
Argus analysis
# FDA Warning Letter Analysis: Eugia Pharma Specialities Limited
**Company and Findings**
Eugia Pharma Specialities Limited, a sterile injectable drug manufacturer based in Hyderabad, India (FEI 3011960448), received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 13, 2026, following an inspection conducted February 16–27, 2026. The FDA determined that the company's manufacturing processes, facilities, and controls do not conform to Current Good Manufacturing Practice (CGMP) regulations, rendering finished drug products adulterated under federal law. The inspection identified significant violations in aseptic processing—the critical method used to manufacture sterile injectables without heat sterilization.
**Regulatory Citations and Their Meaning**
The warning letter cites violations of 21 CFR parts 210 and 211, which establish baseline CGMP requirements for drug manufacturers. Specifically, 21 CFR 211.42(c)(10) requires separate or defined areas with adequate control systems to prevent contamination in aseptic processing, and 21 CFR 211.113(b) mandates written procedures designed to prevent microbiological contamination of sterile products, including process validation. The FDA documented inadequate restricted-access barrier system (RABS) design, frequent uncontrolled operator intervention into ISO 5 critical areas, insufficient environmental monitoring, and poor aseptic technique. These violations represent fundamental breakdowns in the engineering controls and procedural discipline essential to prevent microbial contamination of sterile drugs.
**Response Timeline and Industry Monitoring**
Eugia submitted a response to the FDA Form 483 on March 20, 2026, which the agency found inadequate because it lacked comprehensive retrospective product impact assessment and failed to address underlying design flaws. The warning letter does not specify a response deadline, though industry practice typically allows 15 business days. Compliance officers in the sterile pharmaceutical sector should monitor whether Eugia announces major RABS redesign or line replacement, initiates independent contamination risk assessments, and implements enhanced validation protocols—all prerequisites for regulatory closure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Eugia Pharma Specialities Limited MARCS-CMS 730469 — August 13, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 320-26-115 Product: Drugs Recipient: Recipient Name Mr. Yugandhar Puvvala Recipient Title CEO & Executive Director Eugia Pharma Specialities Limited Galaxy, Floors: 22-24, Plot No. 1, Survey No. 83/1 Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District Hyderabad 500032 Telangana India Yugandhar@eugiapharma.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 13, 2026 WARNING LETTER Reference number: 320-26-115 To Yugandhar Puvvala: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Eugia Pharma Specialities Ltd., Unit 1, FDA Establishment Identifier (FEI) 3011960448, at Sy. No. 550, 551, & 552 Kolthur Village, from February 16 to 27, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 20, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)). Inadequate Design of Facility and Equipment You manufacture sterile injectable dr…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Eugia Pharma Specialities Limited had FDA enforcement actions before?
- Yes. Argus HQ has recorded 3 total FDA actions tied to Eugia Pharma Specialities Limited: 1 warning letter, 0 recalls, and 0 approval records.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Eugia Pharma Specialities Limited, 2026-08-13. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-eugia-pharma-specialities-limited-2026-08-13-cgmp
"CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Eugia Pharma Specialities Limited, 2026-08-13." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-eugia-pharma-specialities-limited-2026-08-13-cgmp.
Argus HQ Research. "CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Eugia Pharma Specialities Limited, 2026-08-13." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-eugia-pharma-specialities-limited-2026-08-13-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_eugia_pharma_specialities_limited_2026_08_13_cgmp_2026,
title = {CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Eugia Pharma Specialities Limited, 2026-08-13},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-eugia-pharma-specialities-limited-2026-08-13-cgmp},
note = {Accessed: August 19, 2026}
}